Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

@inproceedings{Li2010SafetyAP,
  title={Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies},
  author={Jin Li and Xinmin Zhao and Lei Chen and Haiyi Guo and Fangfang Lv and Ka Jia and Ke Yv and Fengqing Wang and Chuan Li and Jun Qian and Chunlei Zheng and Yunxia Zuo},
  booktitle={BMC Cancer},
  year={2010}
}
BackgroundYN968D1 (Apatinib) selectively inhibits phosphorylation of VEGFR-2 and tumor angiogenesis in mice model. The study was conducted to determine the maximum tolerated dose (MTD), safety profile, pharmacokinetic variables, and antitumor activity in advanced solid malignancies.MethodsThis dose-escalation study was conducted according to the Chinese State Food and Drug Administration (SFDA) recommendations in patients with advanced solid tumors to determine the MTD for orally administered… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 95 CITATIONS, ESTIMATED 60% COVERAGE

Apatinib as targeted therapy for sarcoma

  • Oncotarget
  • 2018
VIEW 16 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Apatinib for molecular targeted therapy in tumor

  • Drug design, development and therapy
  • 2015
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway.

  • European journal of pharmacology
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2011
2019

CITATION STATISTICS

  • 6 Highly Influenced Citations

  • Averaged 21 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 17 REFERENCES

AIO Upper GI Group: Sunitinib in patients with chemo-refractory metastatic gastric cancer: Preliminary results of an open-label, prospective nonrandomized multicenter Aio phase II trial

M Moehler, JT Hartmann, +7 authors PR Galle
  • Gastrointestinal Cancers Symposium Abstract
  • 2009
VIEW 1 EXCERPT

Sunitinib in patients with chemo - refractory metastatic gastric cancer : Preliminary results of an open - label , prospective nonrandomized multicenter Aio phase II trial

M Moehler, JT Hartmann, +7 authors PR Galle
  • Gastrointestinal Cancers Symposium Abstract 61
  • 2009

Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.

  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2007
VIEW 1 EXCERPT

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
VIEW 1 EXCERPT

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
VIEW 1 EXCERPT